Rifampin is an antibiotic (8) that reportedly blocks deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase activity in bacterial but not mammalian cells (6, 12, 27) . The drug also interferes with multiplication of three mammalian DNA viruses, adenovirus (25) , poxvirus (vaccinia) (14, 25) , and African swine fever virus (5, 13) , and with viability of transformed chick fibroblasts infected with Rous sarcoma virus (26) . The presence of RNA polymerase activity in poxvirus cores (16) and its induction during poxvirus infection (15) have been demonstrated. It has been suggested that rifampin may inhibit poxvirus multiplication by complexing with a virus-specified polypeptide(s) (RNA polymerase?) needed for virus assembly (19, 21, 22, 24) . This inhibition is rapidly reversed after removal of rifampin in the presence of inhibitors of DNA, RNA, and protein synthesis (21, 23) .
Frog virus 3, a polyhedral cytoplasmic deoxyribovirus (PCDV), resembles poxvirus with respect to its intracellular site of replication and ability to be nongenetically reactivated (11) .
Because nongenetic reactivation is apparently confined to cytoplasmic DNA viruses (7) , this group of viruses may have a common factor(s) (virion-associated RNA polymerase?) required for replication. This factor(s) may be responsible for the sensitivity of animal DNA viruses to rifampin. For these reasons, the effect of rifampin on PCDV multiplication was investigated. The results showed that PCDV multiplication in baby hamster kidney cells in suspension culture (BHK-S) was not significantly inhibited at concentrations of rifampin (100 tig/ml) which blocked multiplication of poxvirus (rabbitpox) from 93 to 99%.
The first experiment was designed to determine the effect of different concentrations of rifampin on PCDV multiplication in BHK-S cells at 28 C, a temperature permissive for infectious virus production (9) . The results (Fig.  1 ) indicated a slight inhibition of virus growth in the presence of 200 ug of rifampin per ml of culture medium. In cultures treated with 400 Ag of rifampin per ml, the 24-h yields of virus were reduced about 90%. There was no effect on the virus latent period (Fig. 1) . Similar results were obtained with monolayer cultures of BHK-S cells infected with PCDV (data not shown).
Since rifampin may interfere with transcription mediated by the transcriptase induced by poxvirus infection (19, 22) , its effects on cellular and PCDV-induced RNA synthesis were determined. By 8 h after infection in the presence of 400 gg of rifampin per ml, PCDV-induced RNA synthesis (20) was suppressed by about 25% (Fig. 2A) , and cellular RNA synthesis (Fig. 2B) was suppressed by about 60%. These data indicate that concentrations of rifampin which inhibit PCDV multiplication also inhibit both virus-induced and cellular RNA synthesis.
Infection with PCDV inhibits cellular DNA synthesis between 0 and 4 h; after 4 h only viral DNA synthesis is detectable (9, 18) . Viral DNA, made exclusively in the cell cytoplasm (9), can be separated by cell fractionation (17) into two classes: replicating DNA (R-DNA) and encapsidated DNA (E-DNA). The next experiment was done to determine the comparative effects of rifampin on these classes of virus-induced (18) . Cells infected at 28 C were either untreated or continuously treated with rifampin starting at 0 h (30 min after the virus attachment period). At various times after infection, duplicate cell samples (5 x 101 cells) were removed and the total virus yield (cell associated plus released virus) was measured by plaque assay (9) . PFU per cell without added rifampin (0) or with 200 (A) or 400 usg (P) of rifampin per ml was measured.
DNA and on cellular DNA synthesis. With or without rifampin treatment, viral R-DNA ( Fig.  3A ) and E-DNA ( Fig. 3B ) formation in PCDVinfected cultures started about 3 h after infection. By 8.5 h after treatment with 400 Ag of rifampin per ml, however, R-DNA and E-DNA formation were inhibited by 50 and 65%, respectively ( Fig. 3A and B) . At 200 jg of rifampin per ml, R-DNA synthesis (Fig. 3A) was inhibited 31% and encapsidation of viral DNA (Fig. 3B) was reduced 42%. In uninfected cells, DNA synthesis (Fig. 3C ) was reduced 29% with 200 yg of rifampin per ml and 59% with 400 Ag/ml.
Although the number of infected cells per sample and the scale for 3H-TdR incorporation differed for virus-induced (Fig. 3A) and cellular ( Fig. 3C ) R-DNA, the data were interpreted in the same way. In other experiments pretreatment of BHK-S cells with rifampin (400 Mg/ml) 1 h before virus infection did not quantitatively alter the observed effect of the drug on PCDVspecific R-DNA or E-DNA formation. In addition, uninfected BHK-S cells in monolayer culture began to show degenerative changes (cell rounding and cell detachment) after incubation for 5 to 8 h at 28 C with 400 but not 200 gg of rifampin per ml. In conclusion, the toxicity of rifampin for the host cell is most likely responsible for the observed reduction in PCDV replication (Fig. 1) at the 400,ug/ml concentration.
Because PCDV multiplication in BHK-S cells was not significantly inhibited by concentrations of rifampin (100 ,Ag/ml) that markedly inhibited poxvirus (vaccinia) multiplication at 37 C (14, 25) plaque assay in BHK-S cell monolayers at 37 C. Residual rifampin in the virus assay was not more than 0.005 yg/ml. The 24-h yield of rabbitpox virus at 28 C (1.9 x 105 PFU/ml) or 37 C (4.4 x 105 PFU/ml) was inhibited 93% with 100 ,g of rifampin per ml and 99% with 200 pg/ml. Thus, BHK-S cells are permeable to antiviral concentrations of rifampin, and the antiviral activity is not dependent on conversion of the drug to an active form at 37 C.
In conclusion, rifampin did not selectively affect PCDV replication in BHK-S cells, because concentrations of the drug (200-400 gg/ ml) that modified PCDV-induced R-DNA (Fig.  3A ) and E-DNA (Fig. 3B) formation, RNA synthesis ( Fig. 2A) , or PCDV multiplication (Fig. 1 ) also caused significant modification of cellular R-DNA (Fig. 3C) and RNA (Fig. 2B) synthesis.
In contrast to my data, Heller (13) reported that rifampin (200 gg/ml) inhibits the total yield of PCDV about 90% in BHK-S cells at 26 C. It is possible that rifampin inhibition of PCDV replication reported by Heller is due to the toxic effects of the drug on BHK-S cells. In agreement with my results, Bingen and Kirn (3) reported that rifampin does not inhibit morphogenesis of PCDV in BHK cells.
Infection of host cells with PCDV markedly inhibits host cell DNA, RNA, and protein synthesis (17, 20) . It is interesting to compare effects of PCDV and rifampin on cellular macromolecular synthesis. During infection with PCDV at temperatures permissive for infectious virus production (28 C), the virus selectively inhibits cellular DNA, RNA, and protein synthesis while allowing continued synthesis of virus-specified macromolecules (17, 18, 20) . At temperatures nonpermissive for virus production (33-37 C) (9, 18) , host-cell synthetic functions are still inhibited. PCDV has also been reported to inhibit vaccinia DNA synthesis in KB cells infected with vaccinia virus (1) . A factor (capsid protein?) closely associated with PCDV may be responsible for this inhibition of viral DNA and host-cell macromolecular synthesis (1, M. Gravell, Bacteriol. Proc., p. 182, 1969).
Preliminary data (Kucera, unpublished data) show that PCDV, like poxvirus, contains an RNA polymerase as an integral component of the virion. There is other evidence supporting these data (10) . However, in contrast to poxvirus cores (19) , in vitro polymerase activity in PCDV cores is inhibited by rifampin (Kucera, unpublished data (Fig. 1) or PCDV-induced transcription in infected BHK-S cells ( Fig. 2A) 
